COVID-19 has pushed the entire health care system to adopt new technologies and new solutions for conducting clinical research and delivering care to patients. An expert panel hosted by the Galien Foundation provided a meditation on what the biopharma industry has learned so far, and how to use the urgency created by COVID-19 to lock-in technological acceleration while maintaining what FDA’s Amy Abernethy called  “responsible progress.”

Johnson & Johnson, among world’s largest health care groups, explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.

As of October 2020, nearly a thousand companies from all industries have committed to climate change-related “Science Based Targets.” However, only 17 signatories are from the pharmaceutical industry, and they are the usual suspects from big pharma. There are none from India and China.

Two years after leading a $46m series B financing round in Inflazome, a four-year old Irish biotech developing oral NLRP3 inflammasome inhibitors, VC firm Forbion is celebrating Roche’s $446m acquisition of the company, which includes the potential for additional milestone payments. Forbion general partner Marco Boorsa, who joined Inflazome’s board of directors in November 2018, spoke with In Vivo about the VC firm’s investment strategy.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

COVID-19 has created an “always accessible” online work environment conducive to executive recruiting, although some candidates are hesitant to change jobs during pandemic-related uncertainty. Corporate culture and an accelerating digital convergence continue to drive hiring decisions, in addition to US immigration policy and a renewed emphasis on diversity, equity and inclusion.